The COVID-19 pandemic has posed several challenges to the global healthcare systems. The diagnostics area is recognized as one of the primary elements of efforts to contain the spread and circumvent its adverse impact globally
The global COVID-19 diagnostics market size is valued at USD 19.8 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 3.1% from 2021 to 2027.
FluroTest’s rapid antigen testing platform will be essential to furthering prompt and accurate viral detection at surge-scale levels, while helping to restore and stimulate social and economic activity.
From sports stadiums, airlines, cruise ships, and concert venues to healthcare facilities, corporate campuses, and universities, to safely open to full capacity and maintain business continuity every environment requires:
We are developing a revolutionary Pandemic Defense and Economic Recovery System that will usher in the ‘the new normal’. It’s first testing system will be Antigen based with a throughput capacity of 2,500 tests per hour. Preliminary LOD 90x lower than the nearest competitor.
Please join us as Bill Phelan, CEO of FluroTest gives an executive presentation on the FluroTest Platform
FluroTest and SNC-Lavalin Sign MoU to Bring Saliva Sample-Based SARS-CoV-2 Testing Solution System to Market in Canada and Beyond CALGARY, AB and MONTRÉAL, May 13, 2021 /PRNewswire/ – FluroTech
Clinical Trial Progresses Across Six Clinical Site Locations Throughout the US CALGARY, AB, May 10, 2021 /CNW/ – FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostics Systems (“FluroTest”
CALGARY, AB, May 4, 2021 /CNW/ – FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and subsidiary FluroTest Diagnostics Systems (“FluroTest” or The Company), a first-mover in surge-scale rapid antigen testing for the detection
Former US Assistant Secretary for Health, Admiral Joxel Garcia, MD, joins FluroTest advisory board to support COVID-19 rapid antigen testing system for the masses. Surging
